These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Consecutive use of different biological therapies in the treatment of psoriasis. Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044 [No Abstract] [Full Text] [Related]
26. Translating new insights into treatment optimisation in multiple sclerosis. Fazekas F; Kieseier BC J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857 [No Abstract] [Full Text] [Related]
27. Psoriasis comorbidities. Gottlieb AB; Chao C; Dann F J Dermatolog Treat; 2008; 19(1):5-21. PubMed ID: 18273720 [TBL] [Abstract][Full Text] [Related]
28. Combination immunosuppressive therapies: the promise and the peril. Robinson MR; Korman BD; Korman NJ Arch Dermatol; 2007 Aug; 143(8):1053-7. PubMed ID: 17709665 [TBL] [Abstract][Full Text] [Related]
29. Treatment failure with rituximab in a patient with pemphigus vulgaris. Weger W; Aberer E J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):387-9. PubMed ID: 18269618 [No Abstract] [Full Text] [Related]
30. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542 [TBL] [Abstract][Full Text] [Related]
31. Steroids versus other immune modulators in the management of allergic dermatoses. Abramovits W; Perlmutter A Curr Opin Allergy Clin Immunol; 2006 Oct; 6(5):345-54. PubMed ID: 16954788 [TBL] [Abstract][Full Text] [Related]
32. Drug insight: novel small molecules and drugs for immunosuppression. Fantini MC; Becker C; Kiesslich R; Neurath MF Nat Clin Pract Gastroenterol Hepatol; 2006 Nov; 3(11):633-44. PubMed ID: 17068501 [TBL] [Abstract][Full Text] [Related]
33. Developments in systemic immunomodulatory therapy for psoriasis. Berger EM; Gottlieb AB Curr Opin Pharmacol; 2007 Aug; 7(4):434-44. PubMed ID: 17627886 [TBL] [Abstract][Full Text] [Related]
35. New drugs help immune system fight cancer. McBride D ONS Connect; 2012 Aug; 27(8):25. PubMed ID: 22873087 [No Abstract] [Full Text] [Related]
36. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. Chong BF; Wong HK Clin Exp Dermatol; 2009 Jul; 34(5):e11-3. PubMed ID: 19040508 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic applications and mechanisms underlying the activity of immunosuppressive oligonucleotides. Klinman DM; Tross D; Klaschik S; Shirota H; Sato T Ann N Y Acad Sci; 2009 Sep; 1175():80-8. PubMed ID: 19796080 [TBL] [Abstract][Full Text] [Related]
38. Intravenous immunoglobulins: a valuable asset in the treatment of a case of septic febrile ulceronecrotic Mucha-Habermann disease. Pyrpasopoulou A; Athyros VG; Karagiannis A; Chrysomallis F; Zamboulis C Dermatology; 2007; 215(2):164-5. PubMed ID: 17684382 [No Abstract] [Full Text] [Related]
39. How to manage infections in the era of biologics? Saraceno R; Chimenti S Dermatol Ther; 2008; 21(3):180-6. PubMed ID: 18564248 [TBL] [Abstract][Full Text] [Related]
40. Rapid response of nail psoriasis to etanercept. Rallis E; Stavropoulou E; Rigopoulos D; Verros C J Rheumatol; 2008 Mar; 35(3):544-5. PubMed ID: 18322982 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]